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A B S T R A C T
The aim of this research was to determine the VEGF A expression in tumor cells and the intratumoral microvessel
density and their prognostic significance in the survival of the subjects. 87 subjects were monitored retrospectively for a
period of 60 to 132 months. The subjects were treated at the Department of Obstetrics and Gynecology of Osijek Univer-
sity Hospital Center, Croatia. We analysed standard clinical, pathohistological and therapeutical prognostic factors,
intratumoral microvessel density and expression of VEGF A. Five-year survival was calculated by the life chart method
and presented graphically by Kaplan-Meier curves. Reaching conclusions on statistical hypotheses in this paper was
done with a reliability level p<0.05. Of the analyzed clinical prognostic factors, those which proved to be statistically sig-
nificant and independent prognostic factors were age and clinical stage of the disease, and of pathohistologic ones it was
the depth of myometrial invasion and VEGF expression. An elevated VEGF expression is associated with deep myome-
trial invasion, poorly differentiated tumors, histologic type and intratumoral microvessel density to a statistically signif-
icant degree. Elevated VEGF expression, age, FIGO stage and depth of myometrial invasion play a significant prognostic
role in patients with endometrial cancer. VEGF receptors could be a target for adjuvant therapy in VEGF positive endo-
metrial cancer.
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Introduction
In the human endometrium angiogenesis occurs peri-
odically as a part of the cyclic growth during the men-
strual cycle1. The angiognenesis initiation phase is a re-
sult of the activation of vascular cells and the activation
of growth factors which accelerate angiogenesis, includ-
ing the basic fibroblast growth factor (bFGF), the vascu-
lar endothelial growth factor (VEGF), the platelet-de-
rived endothelial cell growth factor (PDECGF) and the
tumor necrosis factor alpha (TNFa)2. These citokyne and
other angiogenic molecules can be released by inflamma-
tory cells, mastocytes, macrophagi and various tumor
cells3. Once activated, the endothelial cells start prolifer-
ating and migrating, which results in tube formation and
blood flow4. Tumors larger than 1–2 mm3 require ade-
quate blood support for their growth5. Progressive tumor
growth is angiogenesis-dependent. Many human tumors
can persist in an in situ form for a long period of time
(months and years) in an avascular quiet state. In this
state the tumor may have up to several million cells.
When a part of the cells changes angiogenic phenotype, a
change of balance occurs between the positive and the
negative angiogenesis regulators, the tumor begins to
grow rapidly and it becomes clinically detectable. Stimu-
lated by angiogenic molecules, endothelial cells produce
proteins as growth and survival factors for the tumor
cells6. Findings showing a VEGF which is pronounced,
spread and specific to vascular endothelial cells lead to a
hypothesis that these molecules can play a unique role in
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regulating physiological and pathological blood vessel
growth7. VEGF-A transcription is emphasized as a re-
sponse to hypoxia and activated oncogenes8. A correla-
tion between the VEGF expression and microvascular
density in primary breast and gastric cancer prepara-
tions was noticed9,10. Intratumoral microvessel density
(IMD) is the measure of the overall effect of the an-
giogenesis factor11. Many studies have shown the associ-
ation of IMD with the VEGF expression in the early
stage of breast cancer12, where a multivariation analysis
showed IMD an independent prognostic factor in recur-
rence-free survival time. The work of Kirschner and his
associates has showed that angiogenic factors correlate
with survival when it comes to endometrial cancer. Pa-
tients with low intratumoral microvessel density had an
average survival time of 123 months, whereas patients
with a high microvessel density had 75 months13. In a
study on cervical carcinoma it was demonstrated that the
cellular type also plays a role in the level of secretion of
angiogenic molecules14. Most authors agree that angio-
genetic factors, primarilly VEGF and intratumoral micro-
vessel density as an expression of overall angiogenetic ac-
tivity, play a significant role in evaluating the course of
disease, the malignant potential of the tumor and the
prognosis in patients suffering from endometrial cancer
and other malignoma.
Materials and Methods
Subject
The examination included 87 subjects treated with
primary surgery as a result of endometrial cancer at the
Department of Obstetrics and Gynecology of the Osijek
University Hospital Centre, Croatia. Depending on their
clinical stage, some of the subjects underwent adjuvant
radiation therapy, chemotherapy or hormonal treatment.
The subjects were monitored for a period of 60 to 132
months, and the monitoring ceased as a result of death
by primary or other desease or as a result of the end of re-
search.
Methods
We showed the clinical-pathologic prognostic indica-
tors and method of treatment in all patients.
I. Clinical indicators
1. age
2. menopausal status
3. clinical stage.
The clinical stage was defined by surgico-pathological
criteria, but is necessary to mention that at the time of
our patients treatment lymphadenectomy was not being
applied. Therefore, this indicator is not listed in the anal-
ysis, nor in the surgico-pathological staging.
II. Pathohistologic and cytological indicators
1. histologic type
2. histologic grade
3. depth of myometrial invasion
4. limphovascular space involvement
5. presence of atypical endometrial hyperplasia
6. presence of malignant cells in peritoneal washing
7. intratumoral microvessel density
8. VEGF A expression in tumor cells.
Measuring pathohistologic indicators
For a presentation of pathohistologic indicators an
analysis of archival pathohistologic material was done by
routine methods, according to the criteria accepted by
World Healt organization (WHO), International Society
of Gynecological Pathologists (ISGYP) and International
Federation of Gynecology and Obstetrics (FIGO)15–18. By
analysis of the significance of histologic type for progno-
sis we simply divided the tumors in two groups; those
with a favourable prognosis, where we grouped the endo-
metrioid, viloglandular, secretory, adenoacanthoma and
mucinous tumor type, and those with a unfavourable
prognosis, where we grouped the adenosquamous, clear
cell and mixed tumor type.
Determining the density of intratumoral microvessels
was done by applying the immunohistochemical method.
Tumor tissue fixed by standard techniques and embed-
ded in parafin was used. The primary antibody was the
mouse monoclonal antibody M 3527 for CD-105 (en-
doglin) (DAKO, Kopenhagen, Denmark) in a dilution of
1:50. The location of binding of the primary antibody was
visualized by the LSAB (labelled streptavidin-biotin) tech-
nique (DAKO, Kopenhagen, Denmark). Quantitative mea-
suring of intratumoral microvessel density was done by
determining the vascular hot spots. The vascular hot
spots were localized at low magnification (10 X). That
was followed by counting blood vessels on a high power
field (200 X) and expressed as a median of the number of
blood vessels in five high power fields (HPF). The analy-
sis was done according to the international concensus of
quantification of angiogenesis in solid human tumors11.
Resuslts were analysed on the basis of our own cut-off
value for the number of microvessels. This cut-off value
divides tumors into two groups: the ones with favourable
and the ones with unfavourable prognosis.
Determining VEGF A expression in tumor cells was
done by application of the immunohistochemical me-
thod. The primary antibody was a commercial rabbit
polyclonal anti-VEGF antibody (sc-152, Santa Cruz Bio-
technology, USA), intended for the detection of 165, 189
and 121 amino acid isoform of VEGF A, in a dilution of
1:100. 2 mg were applied per preparation. Immunohisto-
chemical staining was performed by biotinisated second-
ary antibodies, a procedure of streptavidin marked by
horseradish peroxidase (HRP), followed by AEC (amino-
ethil-carbasol) chromogene (DAKO, Kopenhagen, Den-
mark), which gives a red-brow coloration. The intensity
of the red-brown coloration development in the tumoral
cell, as a measure of VEGF expression is proportional to
the amount of the antibody bound to the antigenes. The
intensity of coloration is determined in two levels: 1-neg-
ative – when the intensity of the color is either weaker or
equal in comparison with the nearby non-neoplastic en-
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dometrial gland of the same pathohistologic preparation,
2-positive – when the intensity of the color is stronger in
comparison with the »healthy gland«. All preparations
were evaluated by two independent investigators,and
disagreements were solved with a consensus.
III. Method of postoperative treatment
1. adjuvant radiotherapy
a) pelvic radiation
b) brachytherapy
c) combination of pelvic radiation and brachytherapy
2. chemotherapy
3. hormonal therapy.
Criteria for adjuvant therapy were astablished ac-
cording to surgico-pathological staging, with no insight
in lymphonodi status. Hormonal therapy and chemo-
therapy were often applied as an opportunistic systemic
treatment in infaust patients with an advanced clinical
stage of the disease.
Statistical methods
Five-year survival is calculated by the life chart me-
thod and graphically presented by Kaplan-Meier curves.
Statistical indicators of the survival analysis are based
on a log normal distribution of data. Univariate analysis
was performed by means of a t-test. A simultaneuous ef-
fect of all indicators on the survival prognosis was ana-
lyzed by the multivariation regression method on incom-
plete data, the so called Cox regression test. An c2-test
was used to determine the association of VEGF expres-
sion and intratumoral microvessel density with histo-
logic chracteristics. The cut off for the number of blood
vessels per unit and for age, which best differentiate the
life expectancy, were found as the value of the maximum
c2-test, by means of the proportional risk regression
method. Reaching conclusions on statistical hypotheses
in this paper was done with a significance level p<0.05
for all the tests applied.
Results
In the monitored period 24 subjects out of 87 (27.6%)
died. The overall survival rate in endometrial cancer was
72.4%. Most of the patients die within two years of diag-
nosing.
Clinical indicators
The clinical indicators analyzed were age, menopau-
sal status and clinical stage (Table 1). The average age of
patients included in the study was 64 (range 36–82 years
of age). The cut off age which best differentiates life ex-
pectancy was 65. In the univariate and multivariate anal-
ysis age and clinical stage are statistically significant fac-
tors, and menopausal status is not.
Pathohistologic indicators
Histologic grade, deep of myometrial invasion, posi-
tive peritoneal cytology and the expression of VEGF are
statistically significant patohistological prognostic fac-
tors in univariate analysis, and in multivariate analysis
deep od myometrial invasion and VEGF expression (Ta-
ble 2).
Intratumoral microvessel density (IMD)
The average number of intratumoral blood vessels
was 22.4 (range of 9.8 to 42.6). The average number of
blood vessels in a tumor-unaffected (healthy) endome-
trium was 13.8 (range 4.0 to 32.0). Our own cut off value
was 31 microvessels. According to that criterium 86.2%
of tumors were poorly vascularisated and 13.8% was well
vascularisated. Tumors with a higher microvessel den-
sity had a worse prognosis and their five-year survival
rate was less than 60%, and in the group with lower
microvessel density it was about 75%. This difference in
survival is not statistically significant.
VEGF expression in tumor cells
In the immunohistochemical analysis 50.5% of the tu-
mors were VEGF positive, and 49.5% VEGF negative.
The median survival time in the group of VEGF positive
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TABLE 1
CLINICAL PROGNOSTIC FACTORS
Clinical prognostic factors
Subjects Five-year
survival rate (%)
p-value
Number (n) % Univ. Multiv.
Age 0.005 0.026
<65 46 52.8 84.8
65 41 47.2 58.5
Menopausal status NS NS
premonepausal 9 10.3 77.8
postmenopausal 78 89.7 71.8
Clinical stage <0.00001 0.052
I stage 73 83.9 80.8
other stage 14 16.1 28.6
tumors was 82 months, and in the VEGF negative group
it was 118 months. VEGF positive tumors expresed a sta-
tistically significant unfavourable survival rate (Figure
1). There was an additional analysis of the association
between VEGF expression and other unfavourable patho-
histologic prognostic factors. On the multivariate analy-
sis VEGF expression proved to be an independent prog-
nostic factor in endometrial cancer.
VEGF and the depth of myometrial invasion
Prognosis of the tumor with the depth of invasion of
more than half the myometrial depth depends on VEGF
expression to a statistically significant degree (Table 3).
If the VEGF is positive, five year survival rate is less
than 30%, unlike in those with deep invasion, but with-
out an elevated VEGF expression, in which the ten year
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TABLE 2
PATOHISTOLOGICAL PROGNOSTIC FACTORS
Pathohistological
prognostic factors
Subjects Five-year
survival rate (%)
p-value
Number (n) % Univ. Multiv.
Histologic type
type 1 74 85.1 71.6
NS NS
type 2 13 14.9 76.9
Grade
0.014 NS
G1 26 29.9 76.9
G2 45 51.8 77.8
G3 16 18.3 50.0
Depth of myometrial invasion
<0.0001 0.017
none invasion 3 3.4 100.0
1/2 54 62.1 85.2
>1/2 30 34.5 46.7
LVS involvement
NS NSnone 75 86.2 70.7
with 12 13.8 83.3
Peritoneal cytology
0.0006 NS
positive 7 8.0 28.6
negative 54 62.1 79.7
not done 26 29.9 69.2
IMD
NS NS<31 75 86.2 74.7
31 12 13.8 58.3
VEGF
0.015 0.049positive 44 50.5 63.4
negative 43 49.5 83.7
NS – not significant
Fig. 1. Kaplan-Meier curves for overall survival according
to VEGF expression.
Fig. 2. Kaplan-Meier curves for overall survival according
to VEGF expression when myometrial invasion is >½.
survival rate is 75%. This difference is statistically signif-
icant (Figure 2).
VEGF and the histologic grade
Poorly differentiated tumors with an elevated VEGF
expression have an extremely negative prognosis and the
five-year survival rate is 22.2 % (Table 3). If a poorly dif-
ferentiated tumor does not have an elevated VEGF ex-
pression, the five-year survival rate is 85%. This differ-
ence in survival is statistically significant (Figure 3).
VEGF and intratumoral microvessel density
According to microvessel density the tumors are di-
vided on the basis of the cut-off value criterion. From Ta-
ble 3 it is visible that tumors with an elevated VEGF ex-
pression have a worse survival rate, regardless of the
intratumoral microvessel density, however it is particu-
larly expressed in the group of subjects with microvessel
density 31 and it amounts to merely 28.6%. If a well
vascularisated tumor does not have an elevated VEGF
expression, the overall survival is 83.3% (Figure 4). This
difference in survival is statistically significant, and this
group of subjects represents a high-risk group for a nega-
tive outcome.
Method of postoperative treatment
In 93.1% of subjects one or more adjuvant therapeu-
tic procedures were carried out. Subjects with whom
brachytherapy was carried out had the most favourable
five-year survival (88.0%). Subjects with whom no ra-
diaion therapy was carried out at all had the most un-
faourable five-year survival (40.0%). In univariation
analysis chemotherapy and hormonal therapy were not
statistically significant. Adjuvant therapy in the
multivariate analysis was not a significant prognostic
factor.
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TABLE 3
DEPTH OF MYOMETRIAL INVASION, HISTOLOGIC GRADE, LYMPHVASCULAR SPACE INVOLVEMENT, INTRATUMORAL
MICROVESSEL DENSITY AND VEGF EXPRESSION RELATION
Prognostic factor
VEGF negative VEGF positive
p-value
n (%) Five-year survival rate (%) n (%) Five-year survival rate (%)
Myometrial invasion
none 1 (1.1%) 100.0 2 (2.2%) 100.0 NS
1/2 30 (34.6%) 86.7 24 (27.6%) 83.3 NS
>1/2 12 (13.8%) 75.0 18 (20.7%) 27.8 0.008
Histologic grade
G 1 13 (14.9%) 92.3 13 (14.9%) 61.5 NS
G 2 23 (26.5%) 78.2 22 (25.3%) 77.2 NS
G 3 7 (8.0%) 85.7 9 (10.3%) 22.2 0.007
LVS involvement
no 37 (42.5%) 81.1 38 (43.7%) 60.5 0.039
yes 6 (6.9%) 100.0 6 (6.9%) 66.7 NS
IMD
<31 37 (42.5%) 85.6 38 (43.7%) 67.5 NS
31 5 (5.8%) 83.3 7 (8.0%) 28.6 0.033
NS – not significant
Fig. 3. Kaplan-Meier curves for overall survival according to
VEGF expression with poorly differentiated tumors (G3).
Fig. 4. Kaplan-Meier curves for overall survival with well
vascularisated tumors according to VEGF expression.
Discussion
Endometrial adenocarcinoma is the most common
malignant tumor of the female reproductive system in
Croatia. Generally speaking, given its relatively early di-
agnosing, this tumor can be categorized as a gynecologic
tumor with a positive prognosis. However, about 35% pa-
tients who die of this deasease belong to the group of pa-
tients diagnosed in the first stage. Therefore it is impor-
tant to determine the key risk factors based on which the
patients can be categorized as high-risk or low-risk group,
and modify the therapy approach, the treatment and
monitoring extensity accordingly.
It was to be expected that the intratumoral micro-
vessel density was associated with the outcome and the
survival. Angiogenic molecules of the tumor tissue acti-
vated the creation of a higher number of blood vessels in
comparison to a healthy endometrium (22.4:13.8). Ac-
cording to the cut off number of microvessels (31) 86.2%
of the tumor was poorly, and 13.8% was well vascu-
larisated. Subjects who had tumor with a microvessel
density of 31 and higher had a 20% worse five-year sur-
vival, however this difference showed no statistical sig-
nificance. A similar result was reached by a number of
other authors13,19. This kind of result can in part be at-
tributed to insufficient objectivity and imperfection of
the model of solid tumor angiogenesis quantification.
Nevertheless, most authors agree that intratumoral mi-
crovessel density has prognostic significance, and in so-
me cases it is an independent prognostic factor, also20.
Out of the total number of immunohistochemically
treated tumors, 50.5% of them exhibited an elevated
VEGF expression. The average five-year survival rate in
the group of subjects with an elevated VEGF expression
amounted to 60%, wheareas in the group with negative
expression it was about 85%, which means that subjects
with VEGF positive tumors have statistically significant
unfavourable five-year survival. In the univariate analy-
sis VEGF proved to be a significant prognostic factor. Re-
sults similar to these were published by some other au-
thors as well20. Some of the authors found no association
between elevated VEGF expression and a negative out-
come21,22 or found no elevated VEGF expression in the
tumor compared to healthy tissue23. In tumors which in-
vade more than half of the myometrium there is a statis-
tically significant difference in survival if there is an ele-
vated VEGF expression present. The five-year survival
rate in this group is below 30%. Results of this kind are
reported by some other authors as well24. By comparing
the role of tumor differentiation and VEGF expression,
we found, like other authors25, that an extremely nega-
tive prognosis results from poorly differentiated tumors
(G3) if they have a positive VEGF expression. Of all the
combinations analyzed this one represents the worst
when it comes to survival. Statistically significant is also
the difference in survival between the predictably his-
tologically more favourable tumor types with poor and el-
evated VEGF expression. The former group has a stan-
dard survival rate of 85%, and the latter below 60%.
When we analyzed the association between the VEGF ex-
pression and intratumoral microvessel density, we found
that the VEGF expression changes the prognosis in well
vascularisated tumors with microvessel density 31 to a
statistically significant degree. This group of subjects
represents a group with a high-risk of a negative out-
come, because more than half the patients with a combi-
nation of these two risk factors die within two years of di-
agnosing.
Generally speaking, we can point out that VEGF ex-
pression is a significant prognostic factor in a univariate
analysis, and that in a multivariate analysis it is an inde-
pendent prognostic factor in endometrial cancer. It is sig-
nificantly associated to deep myometrial invasion, poorly
differentiated tumors, histologic tumor type and higher
intratumoral microvessel density. In correlation with all
the prognostic factors, elevated VEGF expression can
bring a negative prognosis. Special notice can be made to
a group of well vascularisated (31 microvessels) and
poorly differentiated tumors, and of those with a deep
myometrial invasion, with an elevated VEGF expression.
The prognosis in these tumors is extremely poor and re-
quires special attention upon determining the extensity
of the treatment. This leads us to the conclusion that the
use of VEGF receptor inhibitors in these high-risk groups
would be justified as a new form of ajduvant therapy.
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VASKULARNI ENDOTELNI ^IMBENIK RASTA I GUSTO]A TUMORSKIH KAPILARA KAO
PROGNOSTI^KI ^IMBENICI U ENDOMETRIJSKOM RAKU
S A @ E T A K
Cilj ovog istra`ivanja bio je odrediti genski izra`aj VEGF A u tumorskim stanicama i vrijednosti tumorske gusto}e
kapilara i njihov prognosti~ki zna~aj za pre`ivljenje ispitanica. Retrospektivno je kroz period od 60 do 132 mjeseca
pra}eno 87 ispitanica, lije~enih u Odjelu za ginekologiju i porodni{tvo Klini~ke bolnice Osijek, Hrvatska. Analizirali
smo standardne klini~ke, patohistolo{ke i terapijske prognosti~ke ~imbenike, gusto}u tumorskih kapilara i izra`aj VEGF
A. Vjerojatnost pre`ivljenja ra~unali smo metodom `ivotnih tablica i prikazali je grafi~ki Kaplan-Meierovim krivuljama.
Zaklju~ivanje o statisti~kim hipotezama u ovom je radu provedeno uz razinu sigurnosti p<0,05. Od analiziranih klini-
~kih prognosti~kih ~imbenika statisti~ki zna~ajnim i neovisnim prognosti~kim ~imbenicima pokazali su se dob i klini~ki
stadij bolesti, a od patohistolo{kih, dubina miometrijske invazije i izra`aj VEGF-a. Povi{en izra`aj VEGF-a statisti~ki je
zna~ajno povezan s dubokom miometrijskom invazijom, slabo diferenciranim tumorima, histolo{kim tipom tumora i
gusto}om tumorskih kapilara. Pove}an genski izra`aj VEGF-a, dob, FIGO stadij i dubina miometrijske invazije imaju
zna~ajnu prognosti~ku ulogu u bolesnica s endometrijskim rakom. VEGF receptori bi mogli biti meta adjuvantne te-
rapije u VEGF pozitivnim karcinomima endometrija.
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